Short answer
Phathom Pharmaceuticals, Inc. (PHAT) filed an 8-K current report with the SEC on October 26, 2026 reporting Item 8.01 (Other Events). FDA opened docket FDA-2026-N-13038 on VOQUEZNA’s exclusivity, with comments due November 23, 2026.
Phathom Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- FDA opened docket FDA-2026-N-13038 on VOQUEZNA’s exclusivity, with comments due November 23, 2026
- BDR challenges FDA’s recognition of VOQUEZNA’s NCE exclusivity through May 3, 2032
- Adverse FDA or court action could accelerate generic ANDA review and VOQUEZNA competition
- Saba Ilac intends to consolidate a related case with BDR’s litigation, broadening competitive risk
- Phathom plans FDA comments and litigation participation to defend exclusivity and future VOQUEZNA sales
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Phathom Pharmaceuticals, Inc. 8-K filings
Get the next PHAT 8-K as it lands
Follow PHAT for push alerts, or ask the research agent what this filing means.